Breast Cancer: Two Years vs One of Adjuvant Rastuzumab

Prof Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, ItalyMedicalResearch.com Interview with:
Prof Aron Goldhirsch
Department of Medicine
European Institute of Oncology
Via Ripamonti 435, 20141 Milan, Italy

MedicalResearch.com: What are the main findings of the study?

Prof. Goldhirsch:  Two years of adjuvant trastuzumab after standard chemotherapy is not more effective than is 1 year of treatment with the drug for patients with HER2-positive early breast cancer.

MedicalResearch.com: Were any of the findings unexpected?

Prof. Goldhirsch:  Hypothetically, the longer duration exposure to adjuvant trastuzumab was expected to yield a longer DFS, similarly to other targeted therapies, like endocrine therapy.

MedicalResearch.com: What should clinicians and patients take away from your report?

Prof. Goldhirsch:  1 year of treatment provides a significant disease-free and overall survival benefit compared with observation (after adjuvant chemotherapy) and remains the standard of care.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Prof. Goldhirsch:  There are several new efficacious drugs for HER2 disease, (TRASTUZUMAB EMTANSINE and PERTUZUMAB).

An intelligent investigation of their role in the adjuvant setting, for the duration of one year, is a relevant task for clinical research in the field.

Citation:

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Lago LD, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; for the Herceptin Adjuvant (HERA) Trial Study Team.

Department of Medicine, European Institute of Oncology, Milan, Italy.
Electronic address: aaron.goldhirsch@ieo.it.

Lancet. 2013 Jul 17. pii: S0140-6736(13)61094-6. doi: 10.1016/S0140-6736(13)61094-6. [Epub ahead of print]

 

No Comments

Sorry, the comment form is closed at this time.